Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking toleranceMAPARA, Markus Y; SYKES, Megan.Journal of clinical oncology. 2004, Vol 22, Num 6, pp 1136-1151, issn 0732-183X, 16 p.Article

Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: Extinction of graft-versus-leukemia effects after conversion to full donor chimerismMAPARA, Markus Y; KIM, Yong-Mi; MARX, Julie et al.Transplantation. 2003, Vol 76, Num 2, pp 297-305, issn 0041-1337, 9 p.Article

Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cellsLENTZSCH, Suzanne; GRIES, Margarete; JANZ, Martin et al.Blood. 2003, Vol 101, Num 9, pp 3568-3573, issn 0006-4971, 6 p.Article

Viral Drug Sensitivity Testing Using Quantitative PCR: Effect of Tyrosine Kinase Inhibitors on Polyomavirus BK ReplicationRANDHAWA, Parmjeet S; FARASATI, Noush A; YUCHEN HUANG et al.American journal of clinical pathology. 2010, Vol 134, Num 6, pp 916-920, issn 0002-9173, 5 p.Article

Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activitySTENGER, Elizabeth O; TURNQUIST, Heth R; MAPARA, Markus Y et al.Blood. 2012, Vol 119, Num 22, pp 5088-5103, issn 0006-4971, 16 p.Article

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damageFENG, Rentian; OTON, Ana; MAPARA, Markus Y et al.British journal of haematology. 2007, Vol 139, Num 3, pp 385-397, issn 0007-1048, 13 p.Article

Anti-CD20- and B-cell receptor-mediated apoptosis : Evidence for shared intracellular signaling pathwaysMATHAS, Stephan; RICKERS, Anke; BOMMERT, Kurt et al.Cancer research (Baltimore). 2000, Vol 60, Num 24, pp 7170-7176, issn 0008-5472Article

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialARMAND, Philippe; NAGLER, Arnon; FAY, Joseph W et al.Journal of clinical oncology. 2013, Vol 31, Num 33, pp 4199-4206, issn 0732-183X, 8 p.Article

C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cellsPAL, Rekha; JANZ, Martin; KARDAVA, Lela et al.Blood. 2009, Vol 114, Num 18, pp 3890-3898, issn 0006-4971, 9 p.Article

Osteopetrosis with micro-lacunar resorption because of defective integrin organizationBLAIR, Harry C; YAROSLAVSKIY, Beatrice B; ROBINSON, Lisa J et al.Laboratory investigation. 2009, Vol 89, Num 9, pp 1007-1017, issn 0023-6837, 11 p.Article

Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cellsMAPARA, Markus Y; KIM, Yong-Mi; WANG, Sheng-Ping et al.Blood. 2002, Vol 100, Num 5, pp 1903-1909, issn 0006-4971, 7 p.Article

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesisKOH, Ki-Ryang; JANZ, Martin; MAPARA, Markus Y et al.Blood. 2005, Vol 105, Num 10, pp 3833-3840, issn 0006-4971, 8 p.Article

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growthRENTIAN FENG; ANDERSON, Gülsüm; GUOZHI XIAO et al.Blood. 2007, Vol 109, Num 5, pp 2130-2138, issn 0006-4971, 9 p.Article

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropeniaPAL, Rekha; MONAGHAN, Sara A; CORTESE HASSETT, Andrea et al.Blood. 2010, Vol 115, Num 3, pp 605-614, issn 0006-4971, 10 p.Article

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1ANDERSON, Gülsüm; GRIES, Margarete; ROODMAN, David et al.Blood. 2006, Vol 107, Num 8, pp 3098-3105, issn 0006-4971, 8 p.Article

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation studyLENTZSCH, Suzanne; O'SULLIVAN, Amy; AGHA, Mounzer et al.Blood. 2012, Vol 119, Num 20, pp 4608-4613, issn 0006-4971, 6 p.Article

Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioningKIM, Yong-Mi; MAPARA, Markus Y; DOWN, Julian D et al.Blood. 2004, Vol 103, Num 2, pp 732-739, issn 0006-4971, 8 p.Article